Advertisement
UK markets close in 1 hour 50 minutes
  • FTSE 100

    8,441.68
    +60.33 (+0.72%)
     
  • FTSE 250

    20,686.84
    +155.54 (+0.76%)
     
  • AIM

    789.71
    +6.01 (+0.77%)
     
  • GBP/EUR

    1.1621
    +0.0010 (+0.08%)
     
  • GBP/USD

    1.2529
    +0.0005 (+0.04%)
     
  • Bitcoin GBP

    50,291.26
    +1,431.36 (+2.93%)
     
  • CMC Crypto 200

    1,302.30
    -55.71 (-4.10%)
     
  • S&P 500

    5,236.07
    +21.99 (+0.42%)
     
  • DOW

    39,576.34
    +188.58 (+0.48%)
     
  • CRUDE OIL

    79.80
    +0.54 (+0.68%)
     
  • GOLD FUTURES

    2,373.70
    +33.40 (+1.43%)
     
  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     
  • HANG SENG

    18,963.68
    +425.87 (+2.30%)
     
  • DAX

    18,783.80
    +97.20 (+0.52%)
     
  • CAC 40

    8,232.23
    +44.58 (+0.54%)
     

Valneva Joins Euronext’s Tech Leaders Index

VALNEVA
VALNEVA

Saint Herblain (France), June 8, 2022Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its inclusion in the Euronext Tech Leaders Index which was launched yesterday by Euronext.

The Euronext Tech Leaders Index is composed of 100+ European Tech companies, which were identified by Euronext either to be leaders in their field or to have a particularly strong growth profile. It aims to strengthen the European Tech sector and be a catalyst for the next generation of Tech leaders.

Thomas Lingelbach, Chief Executive Officer of Valneva said, “We would like to thank Euronext for our inclusion in this new Index which will enhance our visibility as an innovative vaccine company. The dedicated services afforded to us through this initiative will a be a great asset moving forward.”

ADVERTISEMENT

The Euronext Tech Leaders’ initiative is supported by a powerful network of partners including global investment banks as well as French state-owned investment arm Groupe Caisse des Dépôts.

About the Euronext Tech Leaders Index
Euronext Tech Leaders | euronext.com 

About Valneva SE
Valneva is a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The Company takes a highly specialized and targeted approach to vaccine development and then applies its deep understanding of vaccine science to develop prophylactic vaccines addressing these diseases. Valneva has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19.

Media & Investor Contacts
Laëtitia Bachelot-Fontaine
VP Global Communications & European Investor Relations
M +33 (0)6 4516 7099
laetitia.bachelot-fontaine@valneva.com



Joshua Drumm, Ph.D.
VP Global Investor Relations
M +001 917 815 4520
joshua.drumm@valneva.com

 

Attachment